Lung Cancer

Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study

Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study

By

A retrospective study suggested that 60 Gy of neoadjuvant concomitant image-guided radiotherapy is safe and effective in locally advanced NSCLC.

Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC

Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC

By

In the phase 1/2 ECHO-202/KEYNOTE-037 trial, IDO1 inhibitor epacadostat plus pembrolizumab demonstrated antitumor activity in a NSCLC cohort.

Long-Term Data Show Prophylactic Cranial Irradiation Prolongs DFS, Not OS, in Stage III NSCLC

Long-Term Data Show Prophylactic Cranial Irradiation Prolongs DFS, Not OS, in Stage III NSCLC

By

A 10-year updated analysis of a phase 3 trial demonstrated that use of prophylactic cranial irradiation in NSCLC prolonged disease-free survival, but not overall survival.

The Phase 3 Trial of Niraparib as a Maintenance Therapy in SCLC Begins

The Phase 3 Trial of Niraparib as a Maintenance Therapy in SCLC Begins

By

A phase 3 trial examining niraparib as a maintenance drug for platinum-responsive advanced SCLC is being initiated in China.

PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC

PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC

By

Results from Phase 1 expansion cohorts showed that cemiplimab has antitumor activity against relapsed/refractory NSCLC and a safety profile similar to other PD-1 inhibitors.

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline

By

A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.

PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC

PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC

By

The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.

S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease

S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease

By

Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Gefitinib Continuation Therapy May Be Effective in NSCLC Post-Progression

Gefitinib Continuation Therapy May Be Effective in NSCLC Post-Progression

By

Targeted therapies such as EGFR tyrosine kinase inhibitors have improved survival in non-small cell lung cancer, but resistance is a common challenge.

Continuation of Bevacizumab After Progression May Not Improve Survival Outcomes in NSCLC

Continuation of Bevacizumab After Progression May Not Improve Survival Outcomes in NSCLC

By

AvaALL was the first phase 3 study to evaluate bevacizumab across multiple lines of treatment beyond progression in patients with non-small cell lung cancer.

Capmatinib Plus Gefitinib May Be Effective in Some Forms of Resistant Non-Small Cell Lung Cancer

Capmatinib Plus Gefitinib May Be Effective in Some Forms of Resistant Non-Small Cell Lung Cancer

By

Capmatinib has demonstrated preclinical activity in EGFR-mutant and MET-activated non-small cell lung cancer when administered with concurrent EGFR-TKIs.

Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer

Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung Cancer

By

Artificial intelligence techniques are being employed to build complex new multivariate prognostic models for patients with lung cancer and other malignancies.

S-1 Monotherapy May Be as Effective as Platinum-Based Regimens in Non-Small Cell Lung Cancer

S-1 Monotherapy May Be as Effective as Platinum-Based Regimens in Non-Small Cell Lung Cancer

By

Evidence suggests that S-1 monotherapy may be safe and effective in non-small cell lung cancer.

Apatinib May Be an Effective Second- or Third-Line Option in Non-Small Cell Lung Cancer

Apatinib May Be an Effective Second- or Third-Line Option in Non-Small Cell Lung Cancer

By

Apatinib has demonstrated efficacy in the second-line setting for gastrointestinal cancers and may also be effective in non-small cell lung cancer.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

By

FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.

FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer

FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer

By

The decision was based on the ongoing CheckMate-032 phase 1/2 study, in which researchers are investigating nivolumab in patients with advanced or metastatic tumors.

Accelerated Intensity-Modulated Radiotherapy May Improve Outcomes in Localized Lung Cancer

Accelerated Intensity-Modulated Radiotherapy May Improve Outcomes in Localized Lung Cancer

By

Researchers assessed the outcomes of 73 patients with unresectable advanced non-small-cell lung cancer who were treated with 2 different schedules of IMRT: SMART or H-RT.

COPD May Not Affect Survival in Patients With Small Cell Lung Cancer

COPD May Not Affect Survival in Patients With Small Cell Lung Cancer

By

There is a lack of data assessing the impact of chronic obstructive pulmonary disorder on mortality in small cell lung cancer.

Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible

Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible

By

Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.

Asthma Inhalation Therapies

Asthma inhalation therapies including exercise induced bronchospasm (EIB) and asthma maintenance dosing.

Heterogeneity of Drug Resistance in <I>EGFR</I>-Mutant Non-Small Cell Lung Cancer

Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer

By

The heterogeneity of resistance may make it difficult for drug developers to create combination therapies that prevent eventual resistance to osimertinib.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer

Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer

By

Small cell lung cancer, a highly aggressive disease, is diagnosed in 34,000 patients and accounts for nearly 18% of all lung cancer cases in the United States every year.

Osimertinib May Be Effective for CNS Metastases in Non-Small Cell Lung Cancer

Osimertinib May Be Effective for CNS Metastases in Non-Small Cell Lung Cancer

By

Previous studies have demonstrated that osimertinib may have the potential to improve outcomes among patients with central nervous system metastases.

Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung Cancer

Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung Cancer

By

Researchers retrospectively examined 2448 cases of NSCLC submitted to a single diagnostics lab over 3 years.

The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations

The International Association for the Study of Lung Cancer Publishes Liquid Biopsy Recommendations

By

The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.

Stereotactic Body Radiation Therapy May Improve Overall Survival in Early-Stage Lung Cancer

Stereotactic Body Radiation Therapy May Improve Overall Survival in Early-Stage Lung Cancer

By

Though phase 3 studies are ongoing, there is a dearth of evidence that definitively supports the superiority of stereotactic body radiation therapy compared with conventionally fractionated radiation therapy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs